R
OCKVILLE, Md.--PE announced that it has filed with the Securities and Exchange Commission for a follow-on public offering of 1.615 million shares of its Celera Genomics common stock. The number of shares to be sold does not reflect the previously announced two-for-one Celera stock split effective February 18. The net proceeds from the offering are intended primarily to fund Celera’s new product and technology development activities in functional genomics, with an emphasis on proteomics, and personalized health/medicine. Celera also intends to use the capital for general corporate purposes, including possible acquisitions, alliances, or collaborations.
